PL2059260T3 - Kompozycja farmaceutyczna obejmująca hGH do dostarczania doustnego - Google Patents

Kompozycja farmaceutyczna obejmująca hGH do dostarczania doustnego

Info

Publication number
PL2059260T3
PL2059260T3 PL07841440T PL07841440T PL2059260T3 PL 2059260 T3 PL2059260 T3 PL 2059260T3 PL 07841440 T PL07841440 T PL 07841440T PL 07841440 T PL07841440 T PL 07841440T PL 2059260 T3 PL2059260 T3 PL 2059260T3
Authority
PL
Poland
Prior art keywords
hgh
pharmaceutical compositions
oral delivery
oral
delivery
Prior art date
Application number
PL07841440T
Other languages
English (en)
Inventor
Moise Azria
Yatindra Joshi
Rosario Lobrutto
Linda Mindeholm
Ashish Bipin Patel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2059260T3 publication Critical patent/PL2059260T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL07841440T 2006-08-31 2007-08-28 Kompozycja farmaceutyczna obejmująca hGH do dostarczania doustnego PL2059260T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82414006P 2006-08-31 2006-08-31
EP07841440.6A EP2059260B1 (en) 2006-08-31 2007-08-28 Pharmaceutical compositions comprising hGH for oral delivery
PCT/US2007/076932 WO2008027854A2 (en) 2006-08-31 2007-08-28 Pharmaceutical compositions comprising hgh for oral delivery

Publications (1)

Publication Number Publication Date
PL2059260T3 true PL2059260T3 (pl) 2014-03-31

Family

ID=39000473

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07841440T PL2059260T3 (pl) 2006-08-31 2007-08-28 Kompozycja farmaceutyczna obejmująca hGH do dostarczania doustnego

Country Status (14)

Country Link
US (1) US8323688B2 (pl)
EP (1) EP2059260B1 (pl)
JP (1) JP5042312B2 (pl)
KR (1) KR101524880B1 (pl)
CN (2) CN103356997A (pl)
AU (1) AU2007289344B2 (pl)
BR (1) BRPI0716261A2 (pl)
CA (1) CA2661521C (pl)
ES (1) ES2426485T3 (pl)
MX (1) MX2009002314A (pl)
PL (1) PL2059260T3 (pl)
PT (1) PT2059260E (pl)
RU (1) RU2493868C2 (pl)
WO (1) WO2008027854A2 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005995A2 (en) 2005-07-05 2007-01-11 Emisphere Technologies, Inc. Compositions for buccal delivery of human growth hormone
WO2008112836A2 (en) * 2007-03-15 2008-09-18 Novartis Ag Pharmaceutical composition comprising human growth hormon
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
PL2328601T3 (pl) 2008-08-15 2020-07-13 Ironwood Pharmaceuticals, Inc. Formulacje zawierające linaklotyd do podawania doustnego
EP2331077A2 (en) * 2008-09-04 2011-06-15 Ironwood Pharmaceuticals, Inc. Stable forlulation comprising therapeutic polypeptides for oral administration
AU2010207725B2 (en) 2009-01-22 2015-06-11 Novo Nordisk Health Care Ag Stable growth hormone compounds
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
CN106916229A (zh) * 2009-06-08 2017-07-04 阿穆尼克斯运营公司 生长激素多肽及其制备和使用方法
CN102612376A (zh) 2009-08-06 2012-07-25 诺沃-诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
WO2011017502A2 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
MX338357B (es) 2010-01-22 2016-04-13 Novo Nordisk Healthcare Ag Compuestos estables de la hormona de crecimiento.
CN103002918B (zh) 2010-01-22 2016-05-04 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
UA108636C2 (xx) 2010-02-17 2015-05-25 Пептид
EP2595661A1 (en) 2010-07-22 2013-05-29 Novo Nordisk Health Care AG Growth hormone conjugates
SI2603232T1 (sl) 2010-08-11 2020-03-31 Ironwood Pharmaceuticals, Inc. Stabilne formulacije linaklotida
JP6312592B2 (ja) 2011-08-17 2018-04-18 アイアンウッド ファーマシューティカルズ インコーポレイテッド 消化器疾患の治療
WO2014166836A1 (en) 2013-04-05 2014-10-16 Novo Nordisk A/S Growth hormone compound formulation
CN104961687B (zh) * 2015-06-03 2017-07-25 苏州维泰生物技术有限公司 1,2‑二嗪衍生物及其制剂、用途
CA3014164A1 (en) * 2016-02-17 2017-08-24 Genexine, Inc. Pharmaceutical composition comprising recombinant hgh for the treatment of growth hormone deficiency

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350741A (en) * 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
PT831787E (pt) * 1995-06-07 2002-02-28 Alkermes Inc Composicao para libertacao sustentada da hormona de crescimento humano
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO1998034632A1 (en) 1997-02-07 1998-08-13 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DK1007085T3 (da) * 1997-07-04 2002-05-13 Pharmacia Ab Anvendelse af væksthormon i præparater til behandling af insulin-resistens i hjertet
CA2369591C (en) * 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Disodium salts, monohydrate, and ethanol solvates
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
WO2003015822A1 (en) * 2001-08-17 2003-02-27 Novartis Ag 5-cnac as oral delivery agent for parathyroid hormone fragments
TW200403052A (en) * 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
KR20050090430A (ko) * 2002-12-31 2005-09-13 알투스 파마슈티컬스 인코포레이티드 인간 성장 호르몬 결정 및 이것의 제조 방법
AU2004240553A1 (en) * 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
EP1651248B1 (en) * 2003-07-11 2009-09-09 Novartis AG Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
PT1651249E (pt) 2003-07-23 2012-12-21 Novartis Ag Uso de calcitonina em osteoartrite
JP2007505892A (ja) * 2003-09-19 2007-03-15 ファイザー・ヘルス・アクティエボラーグ 向上した成長障害の処置方法
WO2007005995A2 (en) * 2005-07-05 2007-01-11 Emisphere Technologies, Inc. Compositions for buccal delivery of human growth hormone
CN105641686A (zh) * 2005-09-19 2016-06-08 爱密斯菲尔科技公司 N-(5-氯水杨酰基)-8-氨基辛酸的二钠盐的晶形

Also Published As

Publication number Publication date
AU2007289344B2 (en) 2011-04-14
CN101557827A (zh) 2009-10-14
JP5042312B2 (ja) 2012-10-03
JP2010502639A (ja) 2010-01-28
ES2426485T3 (es) 2013-10-23
CA2661521C (en) 2016-04-12
EP2059260B1 (en) 2013-06-19
US8323688B2 (en) 2012-12-04
KR101524880B1 (ko) 2015-06-01
AU2007289344A1 (en) 2008-03-06
BRPI0716261A2 (pt) 2013-08-06
CN103356997A (zh) 2013-10-23
RU2493868C2 (ru) 2013-09-27
WO2008027854A3 (en) 2008-07-03
KR20090045416A (ko) 2009-05-07
US20100247608A1 (en) 2010-09-30
EP2059260A2 (en) 2009-05-20
MX2009002314A (es) 2009-03-20
PT2059260E (pt) 2013-09-03
CA2661521A1 (en) 2008-03-06
WO2008027854A2 (en) 2008-03-06
RU2009111391A (ru) 2010-10-10

Similar Documents

Publication Publication Date Title
PL2059260T3 (pl) Kompozycja farmaceutyczna obejmująca hGH do dostarczania doustnego
EP2152195A4 (en) PHARMACEUTICAL PEPTIDE FOR ORAL ADMINISTRATION
ZA200710734B (en) Compositions for drug delivery
EP2094262A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING PHENANTHRENNEQUINONE-BASED COMPOUND FOR INTESTINAL DELIVERY SYSTEM
EP1968554A4 (en) BIOADHESIVE MEDICATION FORMULATIONS FOR ORAL TRANSMUCOSAL ADMINISTRATION
PT3984528T (pt) Composições farmacêuticas que compreendem nilotinib
EP2001498A4 (en) PHARMACEUTICAL COMPOSITIONS
IL194176A0 (en) Pharmaceutical compositions
GB0625322D0 (en) Pharmaceutical compositions
IL248492A0 (en) Pharmaceutical preparations for administration into the ventricles of the brain
HK1138732A1 (en) Pharmaceutical compositions
EP2035488A4 (en) MICELLES FOR DRUG DELIVERY
IL220800A (en) Stabilized Pharmaceutical Preparations Containing Passoterodine
EP2010162A4 (en) COMPOSITION FOR DISPOSING A MEDICINAL PRODUCT
EP2143424A4 (en) ORAL PHARMACEUTICAL PREPARATION FOR SPECIFIC DELIVERY TO THE COLON
EP1809291A4 (en) PHARMACEUTICAL COMPOSITIONS FOR TRANSDERMAL LEVY
EP2226071A4 (en) COMPOSITIONS FOR ORAL ADMINISTRATION
IL208325A0 (en) Stabilizing lipis compositions for oral pharmaceutical agents
EP2109454A4 (en) PHARMACEUTICAL COMPOSITIONS BASED ON GLP-1
ZA201102405B (en) Pharmaceutical composition for oral administration
EP2197454A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF OLIGONUCLEOTIDES
HK1115054A1 (en) Preparation for oral administration
ZA200904725B (en) GLP-1 Pharmaceutical compositions
GB0622964D0 (en) Pharmaceutical compositions
GB0621623D0 (en) Pharmaceutical compositions